Launching o2h Kickstarter in North America to support early stage biotechs advancing drug discovery

MANHATTAN, N.Y. - Jan. 8, 2026 - PRLog -- o2h Discovery, a preclinical contract research organization (CRO) with a fully integrated, multi-modality drug discovery platform, is pleased to announce the launch of the latest edition of the o2h Kickstarter in "North America." This program is specifically designed to support early-stage biotech companies across North America by providing drug discovery expertise to accelerate early programs toward defined scientific and funding milestones.

North American biotech start-ups (particularly those based in the United States) continue to play a leading role in global drug discovery innovation. By combining strong target biology with advanced approaches such as AI-enabled discovery, precision medicine, and novel therapeutic modalities, these companies are advancing programs across areas including rare diseases, gene therapies, and personalized medicine, translating scientific insight into meaningful patient outcomes.

Early drug discovery can be complex and demanding. Identifying the right starting compounds and understanding how chemical changes affect biological activity often requires the design and testing of many molecules, an effort that can stretch time, budgets, and internal resources, even for well-funded early-stage teams. Recognizing this challenge, o2h Discovery launched the o2h Kickstarter: North America to provide targeted support at a critical stage of discovery.

The program is aimed at companies that have secured initial funding, identified promising drug targets, and demonstrated the potential to scale but require additional chemistry expertise to advance their programs. Through focused chemistry support, the initiative aims to enable companies to generate high-quality chemical matter, de-risk early hypotheses, and progress discovery programs toward investment-ready milestones, ultimately supporting the development of therapies for areas of high unmet medical needs and improving human health.

o2h Discovery has worked closely with venture capital firms and early-stage biotech companies in the United States, supporting multiple programs that have progressed to big pharma acquisitions or NASDAQ IPOs. Through the o2h Kickstarter: North America, o2h Discovery continues its commitment to partnering with emerging biotech innovators to translate strong science into robust and scalable drug discovery programs.

For more information about the award and to apply, visit: o2hdiscovery.co/o2h-kickstarter-north-america/

To read more about the program, click here (https://o2hdiscovery.co/o2h-kickstarter-north-america/).